Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2021-01-18 |
ViGeneron (DE) Daiichi-Sankyo (Japan) |
engineered adeno-associated virus (vgAAV) |
undisclosed |
research |
Ophthalmological diseases |
Research agreement |
2021-01-05 |
Biogen (USA - MA) ViGeneron (DE) |
gene therapy products based on adeno-associated virus (AAV) vectors |
inherited eye diseases |
collaboration
licensing |
Ophthalmological diseases |
Licensing agreement |
2020-12-15 |
Vectivbio (Switzerland) |
|
|
nomination |
|
Nomination |
2020-12-01 |
ViGeneron (DE) WuXi Advanced Therapies (USA - PA) |
VG901 |
retinitis pigmentosa |
development
manufacturing |
Ophthalmological diseases |
Production agreement |
2020-11-04 |
Vectivbio (Switzerland) |
business development officers |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases - Transplantation |
Nomination |
2020-09-16 |
Vectivbio (Switzerland) |
senior vice president and head of global clinical development and medical affairs |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases - Transplantation |
Nomination |
2020-05-26 |
20Med Therapeutics (NL) |
|
|
opening of new premises |
|
Opening of new premises |
2020-03-23 |
Soligenix (USA - NY) the University of Hawaii (USA) |
|
COVID-19, coronavirus infection |
research |
Infectious diseases |
Research agreement |
2020-02-26 |
Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) |
new targets associated with age-related macular degeneration |
Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy |
R&D |
Ophthalmological diseases - Cardiovascular diseases |
Research agreement |
2020-02-12 |
Sangamo Therapeutics (USA - CA) |
member of the board |
|
nomination |
|
Nomination |
2020-02-06 |
Vectivbio (Switzerland) |
chief commercial officer |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases - Transplantation |
Nomination |
2019-12-23 |
Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) |
gene therapy programs for hemophilia A, including SB-525 |
hemophilia A |
licensing - development - commercialisation |
Rare diseases - Genetic diseases - Hematological diseases |
Licensing agreement |
2019-11-26 |
Sangamo Therapeutics (USA - CA) |
member of the board |
|
nomination |
|
Nomination |
2019-11-08 |
Sangamo Therapeutics (USA - CA) |
scientific advisory board |
|
nomination |
|
Nomination |
2019-10-28 |
20Med Therapeutics (NL) |
|
|
nomination |
|
Nomination |
2019-09-30 |
Sangamo Therapeutics (USA - CA) |
senior vice president, chief medical officer |
|
nomination |
|
Nomination |
2019-09-13 |
Gemini Therapeutics (USA) |
CEO |
|
nomination |
Rare diseases - Genetic diseases- Ophthalmological diseases |
Nomination |
2019-07-31 |
Sangamo Therapeutics (USA - CA) |
executive vice president and general counsel |
|
nomination |
|
Nomination |
2019-06-19 |
Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) |
gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders |
Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders |
development - commercialisation |
CNS diseases - Neurodegenerative diseases |
Development agreement |
2019-05-20 |
Voyager Therapeutics (USA-MA) |
head of R&D |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |